CoChat

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

Open access
Hamdouchi, Chafiq, Kahl, Steven D., Patel Lewis, Anjana, Cardona, Guemalli R., Zink, Richard W., Chen, Keyue, Eessalu, Thomas E., Ficorilli, James V., Marcelo, Marialuisa C., Otto, Keith A., Wilbur, Kelly L., Lineswala, Jayana P., Piper, Jared L., Coffey, D. Scott, Sweetana, Stephanie A., Haas, Joseph V., Brooks, Dawn A., Pratt, Edward J., Belin, Ruth M., Deeg, Mark A., Ma, Xiaosu, Cannady, Ellen A., Johnson, Jason T., Yumibe, Nathan P., Chen, Qi, Maiti, Pranab, Montrose-Rafizadeh, Chahrzad, Chen, Yanyun, Reifel Miller, Anne · 2016 · Journal of Medicinal Chemistry
Cited by 62

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The G protein-coupled receptor 40 (GPR40) also known as free fatty acid receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids, resulting in amplification of insulin secretion only in the presence of elevated glucose levels. Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivatives as GPR40 agonists with unique pharmacology, selectivity, and pharmacokinetic properties. Compounds 1 (LY2881835), 2 (LY2922083), and 3 (LY2922470) demonstrated potent, efficacious, and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion during preclinical testing. A clinical study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy. This manuscript summarizes the scientific rationale, medicinal chemistry, preclinical, and early development data of this new class of GPR40 agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.6b00892

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 62

Metadata

Authors
Hamdouchi, C., Kahl, S. D., Patel Lewis, A., Cardona, G. R., Zink, R. W., Chen, K., Eessalu, T. E., Ficorilli, J. V., Marcelo, M. C., Otto, K. A., Wilbur, K. L., Lineswala, J. P., Piper, J. L., Coffey, D. S., Sweetana, S. A., Haas, J. V., Brooks, D. A., Pratt, E. J., Belin, R. M., Deeg, M. A., Ma, X., Cannady, E. A., Johnson, J. T., Yumibe, N. P., Chen, Q., Maiti, P., Montrose-Rafizadeh, C., Chen, Y., & Reifel Miller, A.
Venue
Journal of Medicinal Chemistry
Published
2016-11-11
Volume
59
Issue
24
Pages
10891-10916
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2532977935
Cited by
62
References
7
FWCI
7.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). https://app.cochat.ai/papers/10.1021/acs.jmedchem.6b00892
The paper
Hamdouchi, C., Kahl, S. D., Patel Lewis, A., Cardona, G. R., Zink, R. W., Chen, K., Eessalu, T. E., Ficorilli, J. V., Marcelo, M. C., Otto, K. A., Wilbur, K. L., Lineswala, J. P., Piper, J. L., Coffey, D. S., Sweetana, S. A., Haas, J. V., Brooks, D. A., Pratt, E. J., Belin, R. M., . . . Reifel Miller, A. (2016). The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6b00892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.